The Associated Press @AP
A new Alzheimer’s drug hitting the market is the first with clear-cut evidence that it can at least modestly slow the disease. But it's only for early-stage patients, requires IV doses every two weeks, comes with safety concerns and costs $26,500 a year. https://t.co/YXCJEmxu9R — PolitiTweet.org